Legale ejere | Status | Dato | Andel | Stemmer |
---|
Historik | Fra | Til | Andel | Stemmer |
---|---|---|---|---|
BNY Nominees Ltd. | 25.11.2015 | 10.07.2020 | 66,67-89,99% | 66,67 % |
BNY Nominees Ltd. | 08.07.2015 | 24.11.2015 | 33,33-49,99% | 33,33 % |
Sofinnova Venture Partners IX, L.P | 15.06.2015 | 16.06.2018 | 5,00-9,99% | 5,00 % |
OrbiMed Private Investments V, LP | 24.11.2014 | 16.06.2018 | 5,00-9,99% | 5,00 % |
SOFINNOVA PARTNERS | 24.11.2014 | 24.11.2015 | 20,00-24,99% | 20,00 % |
Zweite TechnoStart Ventures Fonds GmbH & Co. KG i.L. | 09.09.2011 | 16.06.2018 | 5,00-9,99% | 5,00 % |
Datter-/associerede | Status | Dato | Andel | Stemmer |
---|---|---|---|---|
Ascendis Pharma Europe A/S (CVR 44420449) | NORMAL | 06.11.2023 | 100,00% | 100,00% |
Ascendis Pharma Nordics A/S (CVR 44363437) | NORMAL | 05.10.2023 | 100,00% | 100,00% |
Ascendis Pharma Oncology Division A/S (CVR 41034076) | NORMAL | 13.12.2019 | 100,00% | 100,00% |
ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) | NORMAL | 29.06.2012 | 100,00% | 100,00% |
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) | NORMAL | 29.06.2012 | 100,00% | 100,00% |
Ascendis Pharma Endocrinology Division A/S (CVR 32323537) | NORMAL | 29.06.2012 | 100,00% | 100,00% |
Ascendis Pharma Growth Disorders A/S (CVR 32323677) | NORMAL | 29.06.2012 | 100,00% | 100,00% |